MetroPCS says uniquely placed for Clearwire deal
“We think that we might be uniquely positioned to maybe do something with Clearwire,” Carter said, noting MetroPCS could forge a wholesale agreement to use Clearwire spectrum in major metropolitan markets.But Carter said he was looking at all options and also mentioned AT&T Inc (T.N) as a potential source of spectrum if that operator ends up divesting spectrum to gain U.S. government approval for its proposed $39 billion purchase of T-Mobile USA, a Deutsche Telekom AG (DTEGn.DE) unit.Carter’s comment was source of relief for investors in Clearwire, which has most recently been subject to bankruptcy speculation triggered by comments from its biggest client and shareholder Sprint Nextel Corp (S.N) on October 7.MetroPCS shares rose 43 cents or 5 percent to $8.96 after Carter’s presentation. Clearwire shares rose 36 cents to $1.66 on Nasdaq after the comments. Sprint shares were up 23 cents or almost 9 percent at $2.80 on New York Stock Exchange.
RIM says working to prevent more BlackBerry outages
Founder Mike Lazaridis said during a conference call that
the company could not immediately explain why the switch that
caused the outage had failed.Lazaridis again apologized for the disruption and said the
company would work hard to restore the trust of its customers.
Peabody says China clears $4.7 bln Macarthur takeover bid
Chinese regulatory approval was required because China is a
major customer of pulverised coal injection (PCI) metallurgical
coal and Macarthur controls a substantial slice of that market.”This action from MOFCOM now clears the way for us to
complete this transaction in a timely manner,” said Peabody
Energy Chairman and Chief Executive Gregory H. Boyce.Peabody and ArcelorMittal have extended their takeover bid
to Oct. 28.Macarthur has accepted a sweetened offer from Peabody and
Arcelor after failing to find a rival bidder.PEAMCoal currently has a 22.7 percent stake in Macarthur.
Jury hits Teva, McKesson, Baxter in Propofol case: report
Propofol is the same sedative that is at the center of the manslaughter trial of pop star Michael Jackson, who allegedly was administered the drug shortly before his death.The jury ordered the Israeli-based Teva to pay $89.4 million in punitive damages, according to Bloomberg. Baxter was ordered to pay $55.2 million and McKesson, a drug wholesaler, was found liable for $17.9 million, Bloomberg reported.Earlier today, the jury awarded a total of $20.1 million in compensatory damages to the colonoscopy patients.”We believe that the allegations against Teva are without merit and we plan to appeal this decision,” a spokeswoman for Teva told Reuters in a statement.Baxter and McKesson could not immediately be reached for comment.
